Literature DB >> 30004810

Role of the heart in blood pressure lowering during chronic baroreflex activation: insight from an in silico analysis.

John S Clemmer1, W Andrew Pruett1, Robert L Hester1,2, Radu Iliescu1,3, Thomas E Lohmeier1.   

Abstract

Electrical stimulation of the baroreflex chronically suppresses sympathetic activity and arterial pressure and is currently being evaluated for the treatment of resistant hypertension. The antihypertensive effects of baroreflex activation are often attributed to renal sympathoinhibition. However, baroreflex activation also decreases heart rate, and robust blood pressure lowering occurs even after renal denervation. Because controlling renal sympathetic nerve activity (RSNA) and cardiac autonomic activity cannot be achieved experimentally, we used an established mathematical model of human physiology (HumMod) to provide mechanistic insights into their relative and combined contributions to the cardiovascular responses during baroreflex activation. Three-week responses to baroreflex activation closely mimicked experimental observations in dogs including decreases in blood pressure, heart rate, and plasma norepinephrine and increases in plasma atrial natriuretic peptide (ANP), providing validation of the model. Simulations showed that baroreflex-induced alterations in cardiac sympathetic and parasympathetic activity lead to a sustained depression of cardiac function and increased secretion of ANP. Increased ANP and suppression of RSNA both enhanced renal excretory function and accounted for most of the chronic blood pressure lowering during baroreflex activation. However, when suppression of RSNA was blocked, the blood pressure response to baroreflex activation was not appreciably impaired due to inordinate fluid accumulation and further increases in atrial pressure and ANP secretion. These simulations provide a mechanistic understanding of experimental and clinical observations showing that baroreflex activation effectively lowers blood pressure in subjects with previous renal denervation. NEW & NOTEWORTHY Both experimental and clinical studies have shown that the presence of renal nerves is not an obligate requirement for sustained reductions in blood pressure during chronic electrical stimulation of the carotid baroreflex. Simulations using HumMod, a mathematical model of integrative human physiology, indicated that both increased secretion of atrial natriuretic peptide and suppressed renal sympathetic nerve activity play key roles in mediating long-term reductions in blood pressure during chronic baroreflex activation.

Entities:  

Keywords:  atrial natriuretic peptide; baroreflex; blood pressure; modeling; sympathetic nervous system

Mesh:

Substances:

Year:  2018        PMID: 30004810      PMCID: PMC6297821          DOI: 10.1152/ajpheart.00302.2018

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  36 in total

Review 1.  Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models.

Authors:  A C Guyton
Journal:  Am J Physiol       Date:  1990-11

2.  Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.

Authors:  Uta C Hoppe; Mathias-Christoph Brandt; Rolf Wachter; Joachim Beige; Lars Christian Rump; Abraham A Kroon; Adam W Cates; Eric G Lovett; Hermann Haller
Journal:  J Am Soc Hypertens       Date:  2012-06-12

3.  Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension.

Authors:  Thomas E Lohmeier; Terry M Dwyer; Drew A Hildebrandt; Eric D Irwin; Martin A Rossing; David J Serdar; Robert S Kieval
Journal:  Hypertension       Date:  2005-10-10       Impact factor: 10.190

Review 4.  Diverse biological actions of atrial natriuretic peptide.

Authors:  B M Brenner; B J Ballermann; M E Gunning; M L Zeidel
Journal:  Physiol Rev       Date:  1990-07       Impact factor: 37.312

Review 5.  The baroreflex as a long-term controller of arterial pressure.

Authors:  Thomas E Lohmeier; Radu Iliescu
Journal:  Physiology (Bethesda)       Date:  2015-03

6.  Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.

Authors:  Peter W de Leeuw; John D Bisognano; George L Bakris; Mitra K Nadim; Hermann Haller; Abraham A Kroon
Journal:  Hypertension       Date:  2017-03-20       Impact factor: 10.190

7.  Renal responses to chronic suppression of central sympathetic outflow.

Authors:  Radu Iliescu; Eric D Irwin; Dimitrios Georgakopoulos; Thomas E Lohmeier
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

8.  Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension.

Authors:  Kerstin Wustmann; Jan P Kucera; Ingrid Scheffers; Markus Mohaupt; Abraham A Kroon; Peter W de Leeuw; Jürg Schmidli; Yves Allemann; Etienne Delacrétaz
Journal:  Hypertension       Date:  2009-07-20       Impact factor: 10.190

9.  Lowering of blood pressure during chronic suppression of central sympathetic outflow: insight from computer simulations.

Authors:  Radu Iliescu; Thomas E Lohmeier
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-09-21       Impact factor: 2.557

10.  Chronic baroreflex activation restores spontaneous baroreflex control and variability of heart rate in obesity-induced hypertension.

Authors:  Radu Iliescu; Ionut Tudorancea; Eric D Irwin; Thomas E Lohmeier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-02       Impact factor: 4.733

View more
  3 in total

1.  Preeminent role of the cardiorenal axis in the antihypertensive response to an arteriovenous fistula: an in silico analysis.

Authors:  John S Clemmer; W Andrew Pruett; Robert L Hester; Thomas E Lohmeier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-30       Impact factor: 4.733

2.  Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy.

Authors:  John S Clemmer; W Andrew Pruett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-08-19       Impact factor: 5.125

3.  In silico trial of baroreflex activation therapy for the treatment of obesity-induced hypertension.

Authors:  John S Clemmer; W Andrew Pruett; Robert L Hester
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.